Myriad Genetics, Inc. Stock News

SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025. Goldman Sachs 46 th Annual...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON MYRIAD GENETICS, INC. (MYGN),...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MYRIAD GENETICS, INC. (MYGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON MYRIAD GENETICS, INC. (MYGN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR...

Myriad Genetics, Inc. (NASDAQ:MYGN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Matt Scalo - SVP, IR Sam Raha - President & CEO Scott Leffler - CFO Mark Verratti - COO Conference Call Participants Doug Schenkel - Wolfe Research Puneet Souda - Leerink Partners David Westenberg - Piper Sandler Tejas Sawant - Morgan Stanley Sung Ji Nam - Scotiabank Andrew Cooper -...

Highlights First quarter 2025 revenue of $196 million  declined by 3% year-over-year. Excluding headwinds 1 of $16 million, revenue increased 5% year-over-year.

Initiate Buy on Myriad Genetics, trading near multi-year lows with potential for significant growth driven by new offerings and stable core franchises. Strong financials with $158 million in liquidity, improving margins, and a path to profitability by 2025; 2024 revenue grew 11% YoY to $838 million. Key growth drivers include GeneSight, MyRisk, Prolaris, Precise MRD, and FirstGene; significant ...

More than half say genetic testing for mental health medications could reduce concerns More than half say genetic testing for mental health medications could reduce concerns